Combining Epigenetic and Immunotherapy to Combat Cancer

Cancer Res. 2016 Apr 1;76(7):1683-9. doi: 10.1158/0008-5472.CAN-15-2125. Epub 2016 Mar 17.

Abstract

The most exciting recent advance for achieving durable management of advanced human cancers is immunotherapy, especially the concept of immune checkpoint blockade. However, with the exception of melanoma, most patients do not respond to immunotherapy alone. A growing body of work has shown that epigenetic drugs, specifically DNA methyltransferase inhibitors, can upregulate immune signaling in epithelial cancer cells through demethylation of endogenous retroviruses and cancer testis antigens. These demethylating agents may induce T-cell attraction and enhance immune checkpoint inhibitor efficacy in mouse models. Current clinical trials are testing this combination therapy as a potent new cancer management strategy. Cancer Res; 76(7); 1683-9. ©2016 AACR.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy / methods*
  • Epigenomics / methods*
  • Humans
  • Immunotherapy / methods*
  • Neoplasms / therapy*